Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05534984 · ClinicalTrials.gov registry record · Phase 3
Study of Tecovirimat for Human Mpox Virus
A Phase 3 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Terminated
- Registry status
- Phase 3
- Development phase
- 719
- Enrollment target
NCT05534984 is a Phase 3 study that was terminated before completion, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 719 participants.
The verdict
NCT05534984, a Phase 3 study, was terminated before completion, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 719 participants
- Enrollment target
Study Summary
The purpose of this study was to see if tecovirimat is safe and successful at treating mpox. The main questions were whether tecovirimat reduced time to lesion resolution and pain compared to placebo (no treatment).
Interventions
- DRUG Tecovirimat Oral Capsule
- DRUG Placebo for Tecovirimat
- DRUG Tecovirimat Oral Capsule (Open Label)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 719 participants |
| Start Date | 2022-09-08 |
| Est. Completion | 2025-02-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05534984
The ClinicalTrials.gov registry entry for NCT05534984 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 719 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Tecovirimat Oral Capsule is the first listed.
NCT05534984 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05534984 about?
NCT05534984 is a clinical study titled "Study of Tecovirimat for Human Mpox Virus". The purpose of this study was to see if tecovirimat is safe and successful at treating mpox. The main questions were whether tecovirimat reduced time to lesion resolution and pain compared to placebo (no treatment).
What is the current status of trial NCT05534984?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 719 participants. The study started on 2022-09-08. Estimated completion is 2025-02-22.
What interventions are being tested in trial NCT05534984?
The interventions under investigation include: Tecovirimat Oral Capsule (DRUG), Placebo for Tecovirimat (DRUG), Tecovirimat Oral Capsule (Open Label) (DRUG).
Who is sponsoring clinical trial NCT05534984?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.